Context Therapeutics Inc. (CNTX) News
Filter CNTX News Items
CNTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CNTX News From Around the Web
Below are the latest news stories about CONTEXT THERAPEUTICS INC that investors may wish to consider to help them evaluate CNTX as an investment opportunity.
Context Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsExpands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr. Karen Smith and Dr. Luke Walker Cash and cash equivalents of $84.8 million as of September 30, 2024 PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for so |
Context Therapeutics to Participate in Upcoming Investor Conferences in NovemberPHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November: Guggenheim Global Healthcare Conference: Fireside chat on Monday, November 11, 2024, at 3:00 p.m. ET in Boston, MA. UBS Global Healthcare Conference: Fireside chat on Wednesday, November 13, 2024, at 11:45 a.m. P |
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingPHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: |
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging AntibodyContext to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developme |
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Context Therapeutics... |
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year. |
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of DirectorsThe appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategyPHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. “Karen and Luke’s vast e |
Context Therapeutics Reports Second Quarter 2024 Operating and Financial ResultsAnnounced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and reported on recent business highlight |
Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firmsKey Insights Context Therapeutics' significant individual investors ownership suggests that the key decisions are... |
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical OperationsCompany announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company’s two clinical-stage T cell engaging assets to treat solid tumors PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical |